|
Concord Drugs Ltd.
|
Income Statement
|
|
|
You can view the
Income Statement
for the last 5 years.
|
Market Cap. (Rs.)
|
112.04 Cr.
|
P/BV
|
3.02
|
Book Value (Rs.)
|
28.13
|
|
52 Week High/Low (Rs.)
|
93/26
|
FV/ML
|
10/1
|
P/E(X)
|
333.49
|
|
Bookclosure
|
30/09/2024
|
EPS (Rs.)
|
0.26
|
Div Yield (%)
|
0.00
|
|
(Rs. in Crs.)
| Months | 12 | 12 | 12 |
| Source Of Info (AR = Annual Report, PR = Press Release) | AR | AR | AR |
| FaceValue | 10.00 | 10.00 | 10.00 |
| | | | |
| | | | |
| INCOME | | | |
| Revenue From Operations [Net] | 45.24 | 44.92 | 52.08 |
| Total Operating Revenues | 45.24 | 44.92 | 52.08 |
| | | | |
| Other Income | 0.01 | 0.01 | 0.01 |
| Total Revenue | 45.26 | 44.93 | 52.09 |
| | | | |
| EXPENSES | | | |
| Cost Of Materials Consumed | 35.81 | 31.10 | 41.16 |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -0.58 | 2.16 | -0.16 |
| Employee Benefit Expenses | 4.63 | 6.08 | 4.92 |
| Finance Costs | 2.03 | 1.87 | 1.71 |
| Depreciation And Amortisation Expenses | 1.43 | 1.56 | 1.63 |
| Other Expenses | 1.25 | 1.55 | 1.58 |
| Total Expenses | 44.57 | 44.30 | 50.84 |
| | | | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 0.69 | 0.63 | 1.25 |
| | | | |
| Profit/Loss Before Tax | 0.69 | 0.63 | 1.25 |
| | | | |
| Tax Expenses-Continued Operations | | | |
| Current Tax | 0.20 | 0.22 | 0.38 |
| Deferred Tax | 0.15 | -0.06 | -0.12 |
| Total Tax Expenses | 0.36 | 0.16 | 0.26 |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 0.34 | 0.47 | 0.99 |
| | | | |
| Profit/Loss From Continuing Operations | 0.34 | 0.47 | 0.99 |
| | | | |
| Profit/Loss For The Period | 0.34 | 0.47 | 0.99 |
| Consolidated Profit/Loss After MI And Associates | 0.34 | 0.47 | 0.99 |
| | | | |
| OTHER INFORMATION | | | |
| | | | |
| EARNINGS PER SHARE | | | |
| Basic EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Diluted EPS (Rs.) | 0.34 | 0.47 | 1.06 |
